Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc announced that the US Food and Drug Administration (FDA) has granted Priority Review for a supplemental New Drug Application (sNDA) for the company’s Waldenström’s macroglobulinemia combination therapy, ibrutinib (IMBRUVICA)… Continue reading
The following link is to the Cancer Therapy Advisor website featuring the following video
Meletios Dimopoulos, MD, discusses his findings at the ASCO 2018 meeting in Chicago.
Treatment with a combination of ibrutinib and rituximab improved progression-free survival (PFS) over rituximab alone in patients with Waldenström macroglobulinemia (WM), according to results… Continue reading
We would like to thank everyone who was able to attend the New Toronto Support Group meeting in April.
And a special thank you to our guest speaker Dr. Christine Chen
Please click the link below for a copy of… Continue reading